Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
New Delhi, India - In a record-breaking milestone for the global pharmaceutical and wellness industry, Positive Gems - the flagship brand of PstGems Private Limited has officially become the world’s most followed modern pharmaceutical brand, with 800k+ followers on Instagram alone.
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be around $13.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.62 per share was 11.6% above analysts’ consensus estimates.
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on global economies. The U.S. presidential election, a quadrennial event of immense significance, consistently introduces periods of heightened uncertainty and volatility, often culminating
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
